BSE filing, BSE: 544529. Summary written from the filing by ALFA Finder's alert engine.
Aptus Pharma Ltd: key numbers
- Share price
- ₹471.75
- Market cap
- ₹809.0 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 175.1×Sector 45.9×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Preferential Issue
Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.
- Value
- ₹44.78 Cr
Aptus Pharma Investor Presentation: Key Takeaways
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.1 Cr · +200.0% YoY
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months
Other board meeting outcome announcements
All →Cubical Financial Services Board Meeting Outcome
Cubical Financial Services' board approved establishing a new corporate office in North Delhi. No monetary amount or capacity is stated.
Atmastco Board Meeting Outcome
Atmastco Limited's board approved the notice of its 32nd AGM on 25 November 2026, the FY2025-26 Annual Report, a scrutinizer and e-voting arrangements. No material business decision or monetary amount is reported.
Indrayani Biotech Board Meeting Outcome
Indrayani Biotech appointed Ms. N. S. Poornima as Secretarial Auditor for FY 2025-26 to fill a casual vacancy. Company Secretary C.S. Shanmuga Sundar's resignation took effect on 2 November 2026.
Borana Weaves Board Meeting Outcome
Borana Weaves' board approved shifting its registered office to Surat, Gujarat, effective immediately. The change is an administrative address update with no business impact.
Emergent Industrial Solutions Board Meeting Outcome
Emergent Industrial Solutions reconstituted its four board committees, reassigning existing directors across Audit, Nomination, Stakeholders Relationship, and CSR roles. This is routine governance with no financial impact.
Winsol Engineers Board Meeting Outcome
Winsol Engineers' board approved AoA changes to allow voluntary dividend waiver and postal ballot logistics. All decisions are routine governance matters with no material business impact.